Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non-inferior to allopurinol for any outcomes - Long-term use of febuxostat is not associated with an increased risk of death Published in @TheLancet today https://t.co/EvJGPpDCR8